The purpose of this study was to determine the efficacy of rosuvastatin dosed once a week in
patients with a previous statin adverse event. Rosuvastatin once a week was tolerated by 37 …

Statins possess an excellent safety profile and are generally well tolerated when
administered in the standard once-daily dosing regimen. A small percentage of patients …

The aim of this study was to evaluate the efficacy of rosuvastatin twice weekly in 40 patients
intolerant to daily statins. Rosuvastatin twice weekly alone or added to other lipid-lowering …

BACKGROUND: Many patients who could benefit from hydroxymethylglutaryl coenzyme-A
reductase inhibitors (statins) are unable to take statins because of myalgias while taking …

Background Compared with other statins, rosuvastatin has a relatively long half-life, which
may allow for the administration of this medication on an alternate day basis. Objective To …

The safety and tolerability of rosuvastatin were assessed (as of August 2003) using data
from 12,400 patients who received 5 to 40 mg of rosuvastatin in a multinational phase II/III …

Objective: To examine the efficacy and tolerability of rosuvastatin 5 mg at daily and non-daily
dosing regimens. Research design and methods: A retrospective survey was conducted at …

Statins are normally administered for the treatment of dyslipidemia on a daily basis. This
standard dosing regimen is well tolerated by most patients. Occasionally, patients …

The aim of this article is to examine the benefit-risk profile of rosuvastatin at doses of 10 to
40 mg. In dyslipidemic patients, rosuvastatin produced markedly greater reductions in low …

Background: The safety and tolerability of rosuvastatin were assessed using data from
16,876 patients who received rosuvastatin 5–40 mg in a multinational phase II/III/IIIb/IV …